ChemoCentryx adds Pfizer's Feczko to board

ChemoCentryx Inc. said Monday it has added retired Pfizer Inc. executive Joseph Feczko to its board of directors, effective immediately. The Mountain View-based clinical-stage biopharmaceutical company (NASDAQ:CCXI) said Feczko was the senior vice president and chief medical officer of Pfizer and member of its executive leadership team with global responsibilities for all aspects of the company's medical, regulatory and safety activities. He retired in May 2009.

Hyperion's IPO a model for biotech — and that's not all good

Hyperion Therapeutics Inc.’s planned $57.5 million IPO is a story of risk, potential reward and even a hint of desperation.
It is a familiar story of Bay Area biotech initial public offerings, which have been far and few between in the past couple of years. In fact, Hyperion’s back story is not very different from that of Novato’s Raptor Pharmaceutical Corp.: young company, improved drug, small patient population and, possibly, a product on the market by early next year.
But there are some twists and turns in Hyperion’s tale — including one that might catch the interest of federal antitrust investigators.

ChemoCentryx stock up 5% after IPO

ChemoCentryx Inc.'s stock was up nearly 5 percent in afternoon trading on Thursday, at around $10.50 per share. It opened at $10.75 per share.
The Mountain View-based biopharmaceutical company raised $45 million in its IPO on Wednesday, selling 4.5 million shares at $10 each. It is trading under the ticker symbol CCXI.

ChemoCentryx drops IPO target to $45M

ChemoCentryx, the next Silicon Valley initial public offering expected to debut on Nasdaq this week, lowered its IPO target early on Wednesday.
The Mountain View-based biopharmaceutical company has amended its IPO terms to 4.5 million shares at an offering price of $10 per share.

ChemoCentryx sets $14-$16 range for IPO

ChemoCentryx Inc. on Monday set a target range of $14 to $16 for its initial public offering.
The target at the top of the range would bring in $64 million, slightly less than the $69 million the Mountain View biopharmaceutical company filed for back in October.
ChemoCentryx, focused on the treatment of autoimmune diseases, inflammatory disorders and cancer, said it plans to offer 4 million shares. At the mid-point of the proposed range, its market value would be $555 million.

ChemoCentryx refiles IPO plans, seeks to raise $69M

ChemoCentryx Inc. has refiled plans for an initial public offering to raise $69 million, according to a regulatory filing with the U.S. Securities and Exchange Commission.
The Mountain View-based company, which develops oral drugs for autoimmune diseases, inflammatory diseases and oncology, filed for a $57.5 million IPO in 2007, but withdrew the registration citing market conditions. It had hoped to use most of the proceeds to develop treatment of inflammatory bowel disease, and for research and development of other candidates.